Here’s a summary of the press release:
Key Findings
- A one-size-fits-all approach may miss young adults with prediabetes who need more intensive prevention.
- In 662 adults ages 18-40 with prediabetes, the overall 5-year risk of progressing to Type 2 diabetes was 7.5%.
- Risk rose to 10.9% for those who met criteria for GLP-1 receptor agonist (GLP-1RA) weight-loss medication (obesity or overweight + at least one condition like high blood pressure or high cholesterol).
- Risk climbed to 15.1% for those with higher fasting glucose (110–125 mg/dL) and to 24.8% for those with both higher fasting glucose and GLP-1RA eligibility.
Implications
- Using fasting glucose levels plus other risk factors (obesity, high cholesterol, high blood pressure) could help identify young adults who would benefit from earlier, targeted lifestyle interventions or, in some cases, GLP-1RA medication.
- Lifestyle changes—weight loss, healthy eating, regular moderate physical activity—may slow progression and reduce heart/kidney risks.
Context & Caveats
- Presented at the American Heart Association’s EPI|Lifestyle Scientific Sessions 2026 (Boston, March 17–20). The findings are from a research abstract, not yet peer-reviewed.
- GLP-1RAs are FDA-approved for Type 2 diabetes and for weight loss in eligible patients, not for preventing Type 2 diabetes in prediabetes.
- Cost-effectiveness of using GLP-1RAs for prevention isn’t known.
- Study limitations: no hemoglobin A1c data (only fasting glucose); data collected 1985–2011 from three U.S. studies (Hispanic Community Health Study/Study of Latinos, CARDIA, Framingham Heart Study Third Generation). Participants’ mean age was 32; 33% women, 47% Hispanic/Latino, 45% non-Hispanic White, 7% non-Hispanic Black.